Page last updated: 2024-08-21

thiazoles and pd 184352

thiazoles has been researched along with pd 184352 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dent, P; Grant, S; Harada, H; Nguyen, TK; Rahmani, M	1
Druker, BJ; Eide, CA; Hayward, R; Heidorn, S; Marais, R; Niculescu-Duvaz, I; O'Hare, T; Packer, LM; Rana, S; Rebocho, A; Springer, C; Zabriskie, MS	1
Bonkovsky, HL; Hwang, SI; Lee, JG; McKinney, KQ; Mougeot, JL	1

Trials

1 trial(s) available for thiazoles and pd 184352

Article	Year
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood, 2007, May-01, Volume: 109, Issue:9 Topics: Benzamides; Butadienes; Dasatinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles	2007

Article

Year

MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.

Blood, 2007, May-01, Volume: 109, Issue:9

Topics: Benzamides; Butadienes; Dasatinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles

2007

Other Studies

2 other study(ies) available for thiazoles and pd 184352

Article	Year
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer cell, 2011, Dec-13, Volume: 20, Issue:6 Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Genes, ras; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyrimidines; raf Kinases; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2011
Proteomic strategy for probing complementary lethality of kinase inhibitors against pancreatic cancer. Proteomics, 2013, Volume: 13, Issue:23-24 Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Survival; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Heme Oxygenase-1; Humans; Imatinib Mesylate; Indoles; Pancreatic Neoplasms; Piperazines; Protein Kinase Inhibitors; Proteome; Pyrimidines; Pyrroles; Spectrometry, Mass, Electrospray Ionization; Sunitinib; Tandem Mass Spectrometry; Thiazoles	2013

Article

Year

Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.

Cancer cell, 2011, Dec-13, Volume: 20, Issue:6

Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Genes, ras; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyrimidines; raf Kinases; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2011

Proteomic strategy for probing complementary lethality of kinase inhibitors against pancreatic cancer.

Proteomics, 2013, Volume: 13, Issue:23-24

Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Survival; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Heme Oxygenase-1; Humans; Imatinib Mesylate; Indoles; Pancreatic Neoplasms; Piperazines; Protein Kinase Inhibitors; Proteome; Pyrimidines; Pyrroles; Spectrometry, Mass, Electrospray Ionization; Sunitinib; Tandem Mass Spectrometry; Thiazoles

2013